The current International Classification of Diseases, 10th edi- tion, codes have not yet been modified to reflect the new classification from the 2017 Hypertension Clinical Prac- which may create some initial challenges with implementation. The writing committee is sensitive to the fact that the current version (2019 at the time of this writing) of the performance measures for controlling HBP developed by the NCQA for the Healthcare Effective- ness Data and Information Set6 and currently in use in also does not incorporate the 2017 Hyper- tension Clinical Practice Guidelines classification scheme. It is well understood that these measures are already in widespread use, especially for quality-related payment programs promulgated by CMS, such as the Medicare Advantage Stars ratings, the Medicare Shared Savings Program, and the Physician Quality Payment Program, as well as many other programs promoted by commercial health insurers. In particular, the widespread use of the 2017 Hypertension Clinical Practice Guidelines4 classi- fication scheme will also help to guide decision-making about when to prescribe antihypertensive medications in accordance with its current recommendations for the ACC/AHA stages of HBP (ie, stage 2, stage 1, and elevat- ed blood pressure [BP]), as outlined in Table 3. In the 2017 Hypertension Clinical Practice Guide- the authors emphasized the critical importance of measuring atherosclerotic cardiovascular disease (ASCVD) risk for all patients with HBP, regardless of stage. Therefore, it will be important for the end users of the new ACC/AHA performance measure set to incorporate this risk assessment process in order to achieve successful implementation as a key component of quality improvement for patients with HBP. 